Press Releases

Date Title
Toggle Summary Kura Oncology to Present at Stifel Healthcare Conference
SAN DIEGO , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer,
Toggle Summary Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation SAN DIEGO , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced
Toggle Summary Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation at ASH 2019 – – Initiation of first-in-class menin-MLL inhibitor KO-539 gives
Toggle Summary Kura Oncology Appoints James Basta as Chief Legal Officer
– Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experience – SAN DIEGO , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of
Toggle Summary Kura Oncology to Report Third Quarter 2019 Financial Results
SAN DIEGO , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2019 financial results after the close of
Toggle Summary Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
– 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% – – Median progression-free survival of 6.1 months vs. 2.8 months on last prior therapy – – 8 efficacy-evaluable patients enrolled since last update include 3 confirmed PRs, 2 unconfirmed PRs
Toggle Summary Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29 th – – Previously announced poster presentation rescheduled to take place following oral presentation – – Data embargoed until 11:50 a.m.
Toggle Summary Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SAN DIEGO , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s Phase 2 clinical trial of tipifarnib
Toggle Summary Kura Oncology Expands Board of Directors with Appointment of Diane Parks
– Accomplished executive adds extensive experience in launching novel therapies as Company sets sights on commercial readiness – SAN DIEGO , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision
Toggle Summary Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company